Mike B Bayne

Learn More
The chimeric anti-CD20 monoclonal antibody (mAb), rituximab, is an established part of the management of many non-Hodgkin lymphomas. The in vivo action of rituximab remains elusive, and this partially reflects a lack of highly specific reagents to detect rituximab binding at the cell surface. Here we report a new high-affinity mAb (MB2A4) with fine(More)
RIT in “low grade” NHL produces high objective response rates with durable complete responses. The most impressive results, suggesting that there may be a radiation dose response for RIT, have been reported in clinical studies using high myeloablative dose RIT followed by peripheral blood stem cell transplant (PBSCT). The development of a human anti-mouse(More)
BACKGROUND AND PURPOSE This prospective study investigated the impact of radiotherapy (RT)-planning FDG-PET/CT on management of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Patients still eligible for radical RT after conventional staging underwent RT-planning PET/CT and, if disease was still treatable to 60 Gy, they entered our planning(More)
BACKGROUND Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common mechanism, involving reactive oxygen species in the inner ear. Aspirin has been shown to minimise gentamicin-induced ototoxicity. We,(More)
Sir d Patients with advanced non-small cell lung cancer (NSCLC) receive first-line platinum-based chemotherapy, but there is little consensus regarding optimum secondline therapy. In 2008, the National Institute for Health and Clinical Excellence (NICE) published guidance recommending erlotinib [an epidermal growth factor receptor (EGFR) tyrosine kinase(More)
BACKGROUND The use of prophylactic radiotherapy to prevent procedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical practice varies worldwide. We aimed to compare prophylactic radiotherapy with deferred radiotherapy (given only when a PTM developed) in a suitably powered trial. METHODS We did a multicentre,(More)
  • 1